Anemia
Conditions
Interventions
Experimental group: 25 patients undergoing hemodialysis for more than 1 year, using a minimum dose of erythropoietin of 4000 IU per week, assiduous and well-nourished, will receive intravenous 500 mg
Drug
Sponsors
Faculdade de Ciências Médicas
Faculdade de Ciências Médicas
Eligibility
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Be part of a hemodialysis program for chronic kidney disease; Be on erythropoietin in any dose, to control anemia of chronic kidney disease; Perform at least three weekly hemodialysis sessions, with a minimum duration of 4 hours each session; Be assiduous at hemodialysis sessions
Exclusion criteria
Exclusion criteria: Do not use any therapies to control anemia of chronic kidney disease; Be a minor; Chronic ascorbic acid use; Failure of vascular access, such as catheters with low blood flow that prevent hemodialysis with flow above 250 ml / min; Critical worsening of health status, such as prolonged hospitalizations in intensive care units, patients undergoing major surgery with prolonged recovery or patients in palliative care for malignant neoplasms; Little attendance with frequent absences from hemodialysis sessions or undergoing hemodialysis during reduced hours or reduced doses; Any acute or chronic condition that limits the patient's ability to participate in the study, such as advanced heart or liver disease; Have a kidney transplant or recover kidney function in the middle of the study; Malnourished patients, with low body weight, those who use immunosuppressants, chemotherapy, antivirals or immunobiologicals; Patients with a hypersensitivity reaction to some of the research components, such as ascorbic acid or erythropoietin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find the reduction in the dose of erythropoietin necessary to maintain hemoglobin between 10 and 12g / dL, verified by means of a complete blood count, from the observation of the variation of less than 25% in the weekly dose used in the pre and post intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find a reduction of more than 20% in the dose of Parathormone, verified by means of biochemical dosage, from the verification of the variation of 20% in relation to the dosage before the intervention;It is expected to find a reduction in the serum concentration of ferritin and an increase in transferrin saturation, above 20% of the previous values compared, verified by means of serum biochemical measurement.;To evaluate the incidence of respiratory and urinary infections from an individual approach and record in the medical record, analysis of the evolution of each patient and comparison with the incidence prior to the intervention. | — |
Countries
Brazil
Contacts
Public ContactKleber Azevedo
Faculdade de Ciências Médicas
Outcome results
None listed